The Trump administration has been recognized for its initiatives aimed at reducing drug prices, which have had notable impacts on the pharmaceutical landscape.
In contrast, the Biden administration continues to navigate challenges in implementing effective pricing regulations, facing resistance from biotech firms.
The pushback from these companies highlights the complexities of regulatory frameworks and their influence on market dynamics and healthcare accessibility.